L01XX19 • irinotecan • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
Substance: irinotecan
Date of last drug list: 01-01-2021
Commercial code: W67177001
Concentration: 20mg / ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: DREHM PHARMA GMBH - AUSTRIA
Holder: MYLAN IRELAND LIMITED - IRLANDA
Number: 10370/2017/01
Shelf life: 2 years-after packing for marketing;dupa diluare-it is used immediately